Skip to main content

Table 1 Patients' characteristics

From: BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors

Sex
  Male 21 (60%)
  Female 14 (40%)
Age, years
  Median 53  
  Range 27-77  
  < = 45 9 (26%)
  > 45 27 (74%)
Tumor burden (product of largest cross-sectional diameters), mm2
  Median 736  
  Range 20-3519  
  Not measurable n = 8 (23%)
KPS
  Median 70  
  Range 40-90  
  90 7 (20%)
  70-80 15 (43%)
  <70 13 (37%)
Time from diagnosis to start of BCNU, weeks
  Median 38 weeks  
  Range 11-189 weeks  
Primary therapy
  Total resection 15 (43%)
  Partial resection 4 (11%)
  Biopsy 16 (46%)
  Temozolomide 24 (71%)
  Radiation 31 (89%)
Number of relapses at start of BCNU therapy
  First 30 (86%)
  Second 4 (11%)
  Third 0 (0%)
  Fourth 1 (3%)